A Latino MSM Focused Pre-Exposure Prophylaxis Uptake Intervention
Evaluating the Feasibility and Acceptability of a Latino MSM Focused PrEP Uptake Intervention
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ronald A Broooks, PhD
- Phone Number: 310-794-0773
- Email: rabrooks@mednet.ucla.edu
Study Contact Backup
- Name: Omar Nieto, BA
- Phone Number: 310-794-0229
- Email: onieto@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90022
- Bienestar Human Services
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years of age or older
- assigned male at birth
- Identifies as Latino/Hispanic origin
- HIV-negative or HIV status unknown
- Man who has had sex with other men in the past 24 months
- Not currently using PrEP for HIV prevention
Exclusion Criteria:
- Male under 18 years of age
- Not identifying as being of Latino/Hispanic origin
- Man who has not had sex with other men in the past 24 months
- Identifies as cisgender or transgender Female/woman
- Assigned female at birth
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Latino MSM PrEP intervention
The Latino MSM PrEP intervention consists of 4 small group sessions with concurrent peer navigation and counseling.
|
Participants will receive an Information, Motivation, and Behavioral skills model PrEP intervention tailored for mixed immigrant status Latino men who have sex with men
|
|
Active Comparator: Control condition
The control condition consists of usual care at the study site (i.e., referrals to PrEP services).
|
Participants will be offered PrEP navigation services as part of usual care at the study site.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PrEP initiation
Time Frame: assessed at 1-month follow-up
|
We will assess PrEP uptake using evidence of a prescription for Truvada® or Descovy® (participant shows us their prescription bottle in person or via a text photo).
|
assessed at 1-month follow-up
|
|
PrEP initiation
Time Frame: assessed at 3-month follow-up
|
We will assess PrEP uptake using evidence of a prescription for Truvada® or Descovy® (participant shows us their prescription bottle in person or via a text photo).
|
assessed at 3-month follow-up
|
|
PrEP adherence single measure
Time Frame: assessed at 1-month follow-up
|
We will assess adherence to the PrEP medication using a single-item self-rating adherence measure.
|
assessed at 1-month follow-up
|
|
PrEP adherence single measure
Time Frame: assessed at 3-month follow-up
|
We will assess adherence to the PrEP medication using a single-item self-rating adherence measure.
|
assessed at 3-month follow-up
|
|
PrEP adherence urine sample
Time Frame: assessed at 1-month follow-up
|
We will assess adherence to the PrEP medication by analyzing participants' urine sample to determine the presence of the medication tenofovir, a key medication in the PrEP medication.
|
assessed at 1-month follow-up
|
|
PrEP adherence urine sample
Time Frame: assessed at 3-month follow-up
|
We will assess adherence to the PrEP medication by analyzing participants' urine sample to determine the presence of the medication tenofovir, a key medication in the PrEP medication.
|
assessed at 3-month follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Readiness to Adopt PrEP
Time Frame: assessed at 1-month follow-up
|
We will assess changes in readiness to adopt PrEP using the PrEP Transtheoretical Stages of Change Model measure (pre-contemplation, contemplation, preparation, action & initiation, and maintenance).
|
assessed at 1-month follow-up
|
|
Changes in Readiness to Adopt PrEP
Time Frame: assessed at 3-month follow-up
|
We will assess changes in readiness to adopt PrEP using the PrEP Transtheoretical Stages of Change Model measure (pre-contemplation, contemplation, preparation, action & initiation, and maintenance).
|
assessed at 3-month follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ronald A Brooks, PhD, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- IRB#21-002132
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.